CordenPharma and Viking Therapeutics Forge Strategic Alliance for GLP-1 Drug Supply Chain
CordenPharma and Viking Therapeutics: A New Partnership in GLP-1 Therapy Production
In a significant development in the field of metabolic therapies, CordenPharma has announced a multi-year strategic partnership with Viking Therapeutics aimed at supporting the supply chain for Viking's GLP-1 drug candidate, VK2735. This collaboration will involve integrated manufacturing processes spanning large-scale peptide production, injectable formulations, and oral medication preparations.
Overview of the Partnership
On March 11, 2025, CordenPharma confirmed this alliance, emphasizing their commitment to enhancing the commercial availability of VK2735, a Dual GLP-1/GIP Receptor Agonist. The goal of this partnership is to efficiently manage the entire supply chain for VK2735, from the drug substance to the final drug product.
CordenPharma is recognized as a leading Contract Development & Manufacturing Organization (CDMO), notable for its expertise in peptide APIs and peptide therapeutic products. This partnership will not only facilitate the development and manufacturing processes for Viking's innovative treatments but also integrate various stages of manufacture, ensuring both efficiency and reliability.
Integrated Supply Chain
The strategic partnership will leverage CordenPharma's advanced global facilities, which are equipped to handle the complexities of modern pharmaceutical manufacturing. This includes:
- - Large-Scale Peptide Manufacturing: CordenPharma will produce the peptide drug substances essential for VK2735.
- - Sterile Injectable Fill-Finish: The partnership allows for high-precision filling and finishing of injectable versions of the drug, ensuring safety and compliance with health regulations.
- - Oral Solid Dosage Manufacturing: CordenPharma will also develop and manufacture oral tablets, expanding the avenues through which patients can receive treatment.
Dr. Michael Quirmbach, President and CEO of CordenPharma, expressed his enthusiasm for the partnership, stating, “We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities. Our integrated approach will assist in meeting the rising demand for GLP-1 therapies, ultimately leading to improved patient outcomes.”
Enhanced Supply Chain Security
One of the notable features of this collaboration is the redundancy built into CordenPharma's supply network. By utilizing multiple manufacturing sites spread across different regions, CordenPharma aims to provide a secure and uninterrupted supply chain. This integrated approach minimizes the risk of production delays and ensures total compliance with regulatory standards throughout the drug's lifecycle.
About CordenPharma
CordenPharma stands as a dedicated CDMO, committed to supporting biotech and pharmaceutical innovators across various therapeutic modalities. With an extensive operational framework comprising 11 facilities across Europe and North America, CordenPharma provides bespoke services tailored to the specific needs of each client. In the 2024 financial year, the company reported impressive sales figures of €854 million and boasts a workforce of over 3,000 employees.
Following its acquisition by Astorg, a leading private equity firm in the healthcare sector, CordenPharma has accelerated its evolution, focusing on elevating its presence in the peptide space. The partnership with Viking Therapeutics represents a significant opportunity to fortify its position within the competitive landscape of pharmaceutical development and production.
Future Prospects
As the demand for GLP-1 peptides continues to rise, this partnership positions both companies at the frontier of innovative therapies targeting metabolic diseases. The strong collaboration between CordenPharma and Viking Therapeutics is anticipated to yield positive outcomes, not just in operational success, but also in improving patient health outcomes on a broader scale.
For more information on CordenPharma and their services, please visit their official website at cordenpharma.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.